[go: up one dir, main page]

RU2741427C1 - Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик - Google Patents

Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик Download PDF

Info

Publication number
RU2741427C1
RU2741427C1 RU2019139867A RU2019139867A RU2741427C1 RU 2741427 C1 RU2741427 C1 RU 2741427C1 RU 2019139867 A RU2019139867 A RU 2019139867A RU 2019139867 A RU2019139867 A RU 2019139867A RU 2741427 C1 RU2741427 C1 RU 2741427C1
Authority
RU
Russia
Prior art keywords
particles
fraction
ics
mixture
micrometers
Prior art date
Application number
RU2019139867A
Other languages
English (en)
Russian (ru)
Inventor
Алессандро КАВЕККИ
Кристина МЕРУЗИ
Фаусто Пиветти
Франческа Скьяретти
Original Assignee
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. filed Critical КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Application granted granted Critical
Publication of RU2741427C1 publication Critical patent/RU2741427C1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2019139867A 2017-05-11 2018-05-09 Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик RU2741427C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17170632 2017-05-11
EP17170632.8 2017-05-11
PCT/EP2018/061955 WO2018206619A1 (fr) 2017-05-11 2018-05-09 Procédé de préparation d'une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Publications (1)

Publication Number Publication Date
RU2741427C1 true RU2741427C1 (ru) 2021-01-26

Family

ID=58707344

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019139867A RU2741427C1 (ru) 2017-05-11 2018-05-09 Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик

Country Status (12)

Country Link
US (1) US10350164B2 (fr)
EP (1) EP3621589B1 (fr)
KR (3) KR20220155609A (fr)
CN (2) CN119656140A (fr)
BR (1) BR112019023386A2 (fr)
CA (1) CA3059824A1 (fr)
ES (1) ES2882153T3 (fr)
MA (1) MA48620A (fr)
MX (1) MX374484B (fr)
PL (1) PL3621589T3 (fr)
RU (1) RU2741427C1 (fr)
WO (1) WO2018206619A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110582269B (zh) * 2017-05-11 2023-02-28 奇斯药制品公司 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
WO2021058454A1 (fr) 2019-09-24 2021-04-01 Chiesi Farmaceutici S.P.A. Nouvelles particules de support pour formulations de poudre sèche pour inhalation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078693A2 (fr) * 2000-04-17 2001-10-25 Chiesi Farmaceutici S.P.A. Formulations pharmaceutiques pour inhalateurs de poudre seche sous forme de pastilles dures
WO2011076843A2 (fr) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Polythérapie pour bronchopneumopathie chronique obstructive (copd)
RU2453302C2 (ru) * 2006-06-30 2012-06-20 Новартис Аг Композиции для ингаляции, содержащие соли гликопиррония
WO2015004243A1 (fr) * 2013-07-11 2015-01-15 Chiesi Farmaceutici S.P.A. Formulation de poudre sèche comportant un anticholinergique, un corticostéroïde et un bêta-adrénergique pour l'administration par inhalation
EA021901B1 (ru) * 2005-12-12 2015-09-30 Яготек Аг Порошковые композиции для ингаляций

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1131059T3 (da) * 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
DE60239639D1 (de) 2002-07-31 2011-05-12 Chiesi Farma Spa Pulverinhalator
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
EP3160555B1 (fr) 2014-06-30 2019-04-24 Chiesi Farmaceutici S.p.A. Volet pour le mécanisme actionné par inhalation d'un inhalateur de poudre sèche
CN105982880A (zh) * 2015-03-16 2016-10-05 四川海思科制药有限公司 一种干粉吸入剂药物组合物及其制备方法
HRP20200571T1 (hr) * 2015-11-16 2020-07-10 Chiesi Farmaceutici S.P.A. Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik
TWI731891B (zh) * 2015-11-16 2021-07-01 義大利商吉斯藥品公司 含有抗膽鹼劑、皮質類固醇及β-腎上腺素之乾粉配方之製備方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078693A2 (fr) * 2000-04-17 2001-10-25 Chiesi Farmaceutici S.P.A. Formulations pharmaceutiques pour inhalateurs de poudre seche sous forme de pastilles dures
EA021901B1 (ru) * 2005-12-12 2015-09-30 Яготек Аг Порошковые композиции для ингаляций
RU2453302C2 (ru) * 2006-06-30 2012-06-20 Новартис Аг Композиции для ингаляции, содержащие соли гликопиррония
WO2011076843A2 (fr) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Polythérapie pour bronchopneumopathie chronique obstructive (copd)
WO2015004243A1 (fr) * 2013-07-11 2015-01-15 Chiesi Farmaceutici S.P.A. Formulation de poudre sèche comportant un anticholinergique, un corticostéroïde et un bêta-adrénergique pour l'administration par inhalation

Also Published As

Publication number Publication date
BR112019023386A2 (pt) 2020-06-16
MA48620A (fr) 2021-04-28
EP3621589B1 (fr) 2021-07-07
EP3621589A1 (fr) 2020-03-18
US10350164B2 (en) 2019-07-16
KR20190142769A (ko) 2019-12-27
CA3059824A1 (fr) 2018-11-15
KR20220155609A (ko) 2022-11-23
KR20240105510A (ko) 2024-07-05
CN110612095A (zh) 2019-12-24
MX374484B (es) 2025-03-04
KR102637298B1 (ko) 2024-02-20
CN119656140A (zh) 2025-03-21
MX2019012930A (es) 2020-01-14
ES2882153T3 (es) 2021-12-01
WO2018206619A1 (fr) 2018-11-15
PL3621589T3 (pl) 2021-12-06
US20180325815A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
TWI731891B (zh) 含有抗膽鹼劑、皮質類固醇及β-腎上腺素之乾粉配方之製備方法
US10959944B2 (en) Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
CN105338960A (zh) 用于吸入施用的包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂
RU2741427C1 (ru) Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик
RU2742376C1 (ru) Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик
HK40018932A (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
HK40018932B (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
BR112019023378B1 (pt) Processo para preparar uma formulação em pó para inalação para uso em um inalador de pó seco
HK1256859B (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic